EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Insertional Mutagenesis in Hematopoietic Stem-Cell-Based Gene Therapy Trials Using Lentiviral Vectors

Frank J.T. Staal, Christ Leemans, Karin Pike-Overzet

Cancers · 16.11.2026 · 18 (22) · 3664

DOI: 10.3390/cancers18223664 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 16.11.2026. Verfasst von Frank J.T. Staal und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lentiviral vectors enable durable gene correction in hematopoietic stem cells but carry a risk of insertional mutagenesis, potentially leading to clonal expansion and hematologic malignancies. This review examines the mechanisms underlying this risk, recent clinical safety signals, and strategies to improve the safety of gene therapy. Here, we review evidence from clinical trials, mechanistic studies, and preclinical research, focusing on vector integration, promoter activity, clonal hematopoiesis, and treatment-related factors influencing leukemogenesis. Insertional mutagenesis can alter gene expression through enhancer-mediated activation, aberrant transcript formation, and disruption of endogenous regulatory elements. Recent cases of myelodysplastic syndrome and acute leukemia following gene therapy for cerebral adrenoleukodystrophy have highlighted the potential genotoxicity of strong internal promoters, particularly MND. However, outcomes in adenosine deaminase-deficient severe combined immunodeficiency suggest that oncogenic risk is context-dependent. Disease biology, patient age, pre-existing somatic mutations, vector copy number, conditioning regimens, and post-transplant clonal selection may interact to influence malignancy development. In conclusion, insertional mutagenesis remains a clinically relevant challenge despite advances in lentiviral vector design. Integration site analysis and emerging statistical tools, including MELISSA, may facilitate earlier detection of potentially hazardous clonal expansion. Improving safety requires optimized promoter selection, reduced vector copy numbers, enhanced preclinical assessment, individualized risk stratification, and comprehensive long-term surveillance that integrates vector insertion and somatic mutation analyses.

Zitieren

APA

Staal, F. J., Leemans, C., & Pike-Overzet, K. (2026). Insertional Mutagenesis in Hematopoietic Stem-Cell-Based Gene Therapy Trials Using Lentiviral Vectors. Cancers, 18(22), 3664. https://doi.org/10.3390/cancers18223664

Vancouver

Staal FJ, Leemans C, Pike-Overzet K. Insertional Mutagenesis in Hematopoietic Stem-Cell-Based Gene Therapy Trials Using Lentiviral Vectors. Cancers. 2026;18(22):3664. doi:10.3390/cancers18223664

BibTeX
@article{Staal2026,
  author = {Staal, Frank J.T. and Leemans, Christ and Pike-Overzet, Karin},
  title = {Insertional Mutagenesis in Hematopoietic Stem-Cell-Based Gene Therapy Trials Using Lentiviral Vectors},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3664},
  doi = {10.3390/cancers18223664}
}
Kostenlos starten →